Delving into the Latest Updates on Ofloxacin with Synapse

This randomized controlled trial aims to evaluate the effectiveness of intravenous (IV) versus rectal acetaminophen for postoperative pain management in neonates. The study includes postoperative term neonates who require analgesia for at least 12 hours. The main questions the study seeks to answer are:
Does IV acetaminophen provide better pain relief compared to rectal administration in neonates? What is the time to rescue analgesia and the efficacy of pain score reduction between these two routes? The study compares 32 neonates receiving IV acetaminophen to 32 neonates administered rectal acetaminophen. Both routes are administered at equivalent bioavailable doses to ensure a fair comparison.

Start Date10 Jan 2023

Sponsor / Collaborator

Rawalpindi Medical College

NCT05302531

/ RecruitingPhase 1IIT

Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome : a Monocentric Pilot Study

The purpose of this study is to assess the drug absorption of oral antibiotics in patients with short bowel syndrome.

Start Date09 Dec 2022

Sponsor / Collaborator

Centre Hospitalier Regional de Nancy

[+1]

100 Clinical Results associated with Ofloxacin

Login to view more data

100 Translational Medicine associated with Ofloxacin

Login to view more data

100 Patents (Medical) associated with Ofloxacin

Login to view more data

21,618

Literatures (Medical) associated with Ofloxacin

01 Jul 2025·Separation and Purification Technology

Oxygen vacancy modulation S-scheme heterojunction mesoporous BiOBr-CoPc photocatalytic degradation of ofloxacin

Author: Ding, Sheng ; Guo, Jun ; Gan, Wei ; Yan, Kui ; Zhou, Zihan ; Zhang, Miao ; Chen, Ruixin ; Huang, Jingtao ; Zhao, Ziwei ; Liu, Run ; Sun, Zhaoqi

Designing high-performance photocatalysts to achieve efficient degradation of antibiotics by promoting the rapid migration of photogenerated electrons and optimizing surface reaction kinetics has become a research hotspot in the environmental field.Here, mesoporous BiOBr (MBiOBr) was successfully prepared by a chelating ion exchange strategy combined with the hydrothermal method, and CoPc was further introduced through wet treatment to construct the MBiOBr-CoPc heterojunction.MBiOBr-CoPc exhibited excellent photocatalytic degradation of ofloxacin (OFL).The degradation efficiency was as high as 91 % within 16 min, which was 10.3 times that of BiOBr.In addition, the degradation performance of MBiOBr-CoPc was investigated under different OFL concentrations, pH values, water qualities, and anions.It was proved that MBiOBr-CoPc has a wide range of environmental adaptability.Theor. calculations and exptl. results show that the exceptional performance of MBiOBr-CoPc is because of the abundant oxygen vacancies generated by MBiOBr in the lattice mismatch-induced mesoporous formation process.The presence of oxygen vacancies not only strengthens the elec. field effect of the heterojunction interface, but also induces the formation of impurity bands, which can serve as a bridge for electron transfer and promote electron migration.This study provides a useful reference for exploring the mechanism of performance improvement of mesoporous two-dimensional materials in heterojunctions.

01 Jul 2025·Separation and Purification Technology

Molecular engineering of perylene diimide polymers to enhance photocatalytic performance for efficient photodegradation of ofloxacin

Author: Yu, Weili ; Fang, Ningjie ; He, Chuanshu ; Chu, Yinghao ; Lai, Bo ; Huang, Chenxi

The field of photocatalytic degradation has garnered considerable attention for perylene diimide (PDI), primarily because of their exceptional stability, distinctive optoelectronic properties, and outstanding charge transport efficiency.Nevertheless, the limited efficiency of photoinduced charge carrier utilization and poor recyclability pose challenges for real-world photocatalyst applications.We developed three polymers, m-PDI, p-PDI, and o-PDI, by reacting PDI with various benzene diamine compounds at different connection positions, aiming to improve the separation efficiency of photoinduced charge carriers.These unique connection sites resulted in variations in surface area, energy level distribution, and the migration and separation behaviors of photogenerated charge carriers within the polymers.Among the materials, m-PDI demonstrated the largest sp. surface area along with the most deeply positioned valence band.Furthermore, its unique structure enabled stronger interactions with ofloxacin (OFL), facilitating more effective electron transfer from the OFL mols. to the catalyst compared to both p-PDI and o-PDI.Consequently, under light irradiation, m-PDI demonstrated outstanding photocatalytic efficiency, achieving a degradation rate constant of 0.07481 min^-1 within 60 min.This performance was approx. 4 times higher than that of p-PDI and 7 times greater than o-PDI.Addnl., the m-PDI composite showed excellent stability and resilience during recovery experiments and photocatalytic degradation tests in complex aquatic environments.Finally, LC-MS anal. was applied to predict degradation intermediates and pathways for OFL.This work opens up new possibilities for utilizing high-performance organic materials in the eco-friendly treatment of antibiotic-containing wastewater and provides valuable insights into their design principles.

01 Jun 2025·Separation and Purification Technology

Electronically regulated Mn-N site-loaded MXenes for highly efficient and selective singlet oxygen generation via PMS activation

Author: Liu, Zhen ; Yuan, Shiyu ; Zheng, Peng ; Gao, Shikun ; Yuan, Shaochun ; Chen, Yao ; Yang, Shanshan ; Zhang, Zhe ; Ji, Fangfang

In this study, a novel catalyst featuring dual-reactive sites of transition metal and nonmetal is presented, which modifies electronic polarization to enhance the selective generation of singlet oxygen (¹O₂), resulting in effective degradation of antibiotics.Using MXenes as a substrate, a structurally stable Mn-N@MXenes catalyst with controllable reactive sites was synthesized via a hydrothermal method by adjusting the content of the Mn-N precursor.The study revealed that the loading of Mn-N active sites changes the electronic structure and polarization of MXenes, resulting in asym. electronic structures and the generation of numerous oxygen vacancies.These characteristics enable the Mn-N@MXenes/PMS system to selectively generate ¹O₂ and superoxide radicals (O^•-₂), with a synergistic index of 5.77.Compared to the MXenes/PMS system, the Mn-N@MXenes/PMS system significantly boosts the degradation efficiency of ofloxacin (OFL) from 71.32% to 96.07% under optimal conditions.The results demonstrate that during PMS activation, the catalyst maintains a nearly constant degradation rate after four cycles, exhibiting excellent stability and recyclability.Furthermore, the system shows superior performance and environmental adaptability in degrading actual water matrixes and other pollutants.This study reveals electronic regulation mechanisms in catalyst design that facilitate pollutant degradation via both radical and non-radical pathways, offering new strategies for efficient degradation

2

News (Medical) associated with Ofloxacin

20 Mar 2018

·archivelfarma.com

Archivel Farma and Laboratorios Silanes to collaborate in the development of the anti-tuberculosis vaccine RUTI® in México

RUTI® is the most promising therapeutic vaccine among the dozen projects that are currently being developed in the world. Laboratorios Silanes brings to the agreement their extensive knowledge of the regulatory environment and the Mexican pharmaceutical market. Barcelona/Mexico DF, March, 20 2018. Archivel Farma, owner of RUTI®, the most promising therapeutic vaccine targeting tuberculosis, among the dozen RUTI® related projects that are currently being developed around the world, and Laboratorios Silanes, one of the major Mexican pharmaceutical companies, have signed a collaboration agreement for the clinical development and commercialization of the vaccine in Mexico. Under that agreement, Archivel Farma will continue managing the Clinical Development Plan for RUTI® providing Silanes with access to the essential confidential information as well as the Scientific Advisory Committee. Silanes, in turn, will advise Archivel Farma with regard to the regulatory affairs and the recommended clinical development of the vaccine in Mexico and will also evaluate the commercial potential of RUTI® in the Mexican market. The agreement grants Laboratorios Silanes a preferential position in obtaining the licence and distribution rights (L&DA) for RUTI® in Mexico. RUTI® was designed as a therapeutic vaccine for the treatment (not prevention) of different forms of tuberculosis (TB), meant mainly as a solution to treat Multidrug-Resistant Tuberculosis (MDR-TB) and as coadjuvant for the standard antibiotic treatment to avoid the frequent relapses associated with TB. The RUTI® vaccine, originally designed by Dr. Pere-Joan Cardona, Head of the Experimental Tuberculosis Unit at Institut Germans Trias i Pujol (IGTP) in Badalona (Spain) and the founder and scientific advisor at Archivel Farma, is based on cell wall nanofragments of Mycobacterium tuberculosis, the bacillus causing the disease. RUTI® triggers a polyantigenic response that enhances the immune response of the patient, which contributes to combating Mycobacterium tuberculosis and promotes its elimination. TB-causing bacteria can remain latent in the body for decades. It is estimated that each year 90 million people are infected and approximately 10% of them develop tuberculosis. According to WHO, in 2016 10.4 million new TB cases were diagnosed and there were nearly 1.7 million associated deaths (374.000 of which were people with HIV/AIDS). In recent years the number of people suffering from TB resistant forms to the first-line of antibiotics (Isoniazida and Rifampicin) has considerably increased. The WHO calculate that there are 490.000 people with MDR-TB and 100.000 with Rifampicin-resistant tuberculosis worldwide. These patients need to be treated with the second-line of antibiotics (aminoglycosides, Ethionamide, Ethambutol and Ofloxacin) which have many more side effects and show only 60% of efficacy, which results in 250.000 annual deaths caused by MDR-TB. Even though the WHO has recommended new protocols including a shorter medication administration time, in many countries a 21 months’ treatment is still applied, which, in turn, generates high rates of treatment dropout with the corresponding rise in the antibiotic resistances and the associated deaths. According to WHO, 22.200 new cases of tuberculosis were reported in Mexico in 2016 and more than 2900 people died from this infectious disease (770 of them, affected by HIV/AIDS). About 2.6 per cent of new cases of TB in Mexico are resistant to the first-line of antibiotics (MDR/RR-TB), which corresponds to 600 cases per year. Thanks to its strong ability to stimulate the immune response, demonstrated in preclinical and clinical studies, a dose of the RUTI® vaccine combined with antibiotics can reduce the treatment time of MDR-TB and contribute to reducing both the number of deaths and the rate of relapse. For this reason, Archivel Farma have focused their efforts on the development of RUTI® in this context and has initiated phase IIa clinical trials to evaluate the safety and immunogenicity of the vaccine. Furthermore, a study has already started in the Netherlands and it is expected soon to extend to Romania. Archivel plan to start to evaluate the efficacy of the vaccine for the treatment of MDR-TB in early 2020. The agreement between Archivel Farma and Laboratorios Silanes has been managed by trifermedCBDO (www.trifermed.com), the first Contract Business Development Organization with a direct presence in Europe and America. About Laboratorios Silanes Laboratorios Silanes is a Mexican company with an international presence, with 75 years of experience in the pharmaceutical sector. Laboratorios Silanes has operations in the US, Central America, the Caribbean, Brazil, most of Latin America, as well as Europe, Africa and the Middle East. Their products are manufactured with the highest quality standards. They develop medicines for diabetes – their main specialty- cardiovascular diseases, acute and chronic pain. Laboratorios Silanes own more than 160 patents thanks to their strong commitment to innovation, a key factor that has led to the creation of new divisions of diagnosis and biological antidotes to treat poisonous stings and/or bites from venomous animals. www.silanes.com.mx About ArchivelFarma Archivel Farma was founded in 2005 as a spin-off of Archivel Technologies and is based in Badalona, Spain. Archivel Farma has specialised in the discovery and development of new biopharmaceutical agents to prevent and treat tuberculosis and other diseases susceptible to immunological interventions. Developing their products up to advanced clinical phases, Archivel Farma aims to work with partners to bring their products to the market, thus enabling a great number of people to benefit from them. www.archivelfarma.com Contact for media: Adela Farré • afarre@biobiz-communications.com • T. +34 626 992 057 Hugo Lobato (México, CDMX) • lobatoh@cefrp.com.mx • T. +55 5543 0972 ext. 101 Archivel EU Project General Press release Research Fogars de Tordera, 61 Pol. Ind. Bonavista 08916 Badalona T: +34 93 497 24 56 F: +34 93 497 24 57 archivel@archivelfarma.com Privacy policy Cookies policy © 2024 Archivel Farma | Innovative Products. About Us Mission & Values Team Funding Partnership News Our Services GMP facilities Contract manufacturing Analysis Ruti® Project Ruti® Project Fighting TB Pipeline Scientific Advisors Collaborations Contact Mission & Values Team Funding Partnership News GMP facilities Contract manufacturing Analysis Ruti® Project Fighting TB Pipeline Scientific Advisors Collaborations

VaccinePhase 2License out/in

14 Jan 2016

·renovatherapeutics.com

Renova Therapeutics appoints Dr. Richard ‘Mac’ McCloskey to head company’s clinical development efforts

Dr. McCloskey to lead clinical development An author of more than 100 peer-reviewed papers and editorials as well as three books, Dr. McCloskey has led an illustrious career in medical research and clinical practice. He has directed registration trials for Hoffman LaRoche and Centocor and was, most recently, Vice President of Scientific Affairs at Johnson & Johnson Development Corporation as well as a scientific adviser to Endo Pharmaceuticals. As Executive Vice President of Clinical Development for Renova Therapeutics, Dr. McCloskey will be responsible for all clinical aspects of the company’s trials, including preparation of trial synopses and protocols, review and approval of case report systems and safety reporting, and drafting of clinical trial endpoints. He will also ensure Renova Therapeutics meets all regulatory requirements for clinical trial safety reporting, and, as needed, will present trial data to regulatory agencies. In this role, Dr. McCloskey will work closely with the Senior Vice President of Regulatory Affairs and Quality Assurance and will coordinate with the company’s expert consultants on statistical analysis, trial planning and conduct. His immediate focus will be on Renova Therapeutics’ lead investigational product RT-100, a single-dose gene therapy for the treatment of congestive heart failure, which recently completed a Phase 2 clinical trial. “We’re excited to have Mac join Renova as we progress further with our product pipeline,” said Jack W. Reich, Ph.D., CEO and Co-founder of Renova Therapeutics. “His contributions in the medical field and in clinical development will be a tremendous asset to our team, as we continue to develop a portfolio of gene therapies for cardiovascular and metabolic diseases.” Dr. McCloskey received a master’s in microbiology and an M.D. from the University of Rochester and completed his medical training at Duke University and the National Institutes of Health. He has been on the faculty of the University of Texas, the University of Pennsylvania and Jefferson Medical College, and he is an emeritus fellow of the American College of Physicians and the Infectious Disease Society of America. His FDA-approved submissions include interferon, ceftriaxone, infliximab, abciximab, midazolam and injectable testosterone. He also contributed to the following as an academic clinical investigator: cefoxitin, thienamycin, cefotaxime, mezlocillin, ticarcillin, imipenem-cilastatin, cefmenoxime, amdinocillin, fleroxacin and ofloxacin. To him, taking on this role is personal: “Having been treated for congestive heart failure by the single procedure of surgical aortic valve replacement, I have both a personal and scientific appreciation of the breakthrough potential of a single treatment for CHF,” says McCloskey. “And the data derived so far for RT-100 demonstrates that potential.”

Phase 2Executive ChangeGene Therapy

100 Deals associated with Ofloxacin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00453	Ofloxacin	S01AE01 S02AA16 J01MA01	DB01165

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Corneal Ulcer	United States	Allergan, Inc.	30 Jul 1993
Trachoma	Japan	Santen Pharmaceutical Co., Ltd.	01 Jun 1989
Blepharitis	Japan	Santen Pharmaceutical Co., Ltd.	30 Jun 1987
Conjunctivitis	Japan	Santen Pharmaceutical Co., Ltd.	30 Jun 1987
Dacryocystitis	Japan	Santen Pharmaceutical Co., Ltd.	30 Jun 1987
Hordeolum	Japan	Santen Pharmaceutical Co., Ltd.	30 Jun 1987
Keratitis	Japan	Santen Pharmaceutical Co., Ltd.	30 Jun 1987
Bacterial Infections	Japan	Novartis Pharma AG	16 Apr 1985
Otitis Externa	Japan	Alfresa Pharma Corp.	16 Apr 1985
Otitis Media	Japan	Alfresa Pharma Corp.	16 Apr 1985

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute otitis media	Discovery	-	Daiichi Sankyo, Inc.	01 Nov 2002

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02528123 (CTgov)	Not Applicable	Myopia	114	Small incision lenticule extraction+Tobramycin+Proxymetacaine 0.5%+Oxybuprocaine 0.4%+dexamethasone+Ofloxacin	xstdgkjula(hrfygmnzcc) = pxawknsomu tcnlnesqpi (uknnlqiszh, cgenuvzgld - tivvsuryef) View more	-	23 Apr 2024
NCT02567825 (CTgov)	Not Applicable	Acute otitis media	250	Tympanostomy tube placement+Ofloxacin Otic (Surgical Management)	kepydjsqlq(ytybyvptgb) = rggmvkowau ntmuwiwuud (apwkvzgsxk, rjcytcidtp - lwajqhyzhz) View more	-	10 Dec 2021
				Ceftriaxone+Amoxicillin-Clavulanate (Non-Surgical Management)	kepydjsqlq(ytybyvptgb) = ajmvqtdrnn ntmuwiwuud (apwkvzgsxk, ssvmgjamty - slhhxzxzsk) View more
NCT02373137 (DETECT, CTgov)	Phase 4	Corneal Diseases \| Keratoplasty rejection	38	DMEK+Tropicamide+phenylephrine+prednisolone+Ofloxacin (DMEK)	frrjpocscj(wfqpuofdwx) = djahprwmzr czgtyjyioc (xcunxvkbhj, lsmxdamgpz - dxfxpoylfr) View more	-	02 Jul 2019
				DSAEK+Tropicamide+phenylephrine+prednisolone+Ofloxacin (DSAEK)	shkcryoaly(kutcglogax) = jieaxesefd hwipvylutx (kfgacpserq, grtfvlfzbg - sllevwttcu) View more
ISRCTN63006567 (Pubmed \| PLoS Negl Trop Dis)	Not Applicable	Typhoid Fever	627	Gatifloxacin	(guvrkilojb): HR = 0.81 (95% CI, 0.25 - 2.65), P-Value = 0.73 View more	Negative	01 Jan 2013
				Ofloxacin
IAS2009	Not Applicable	Tuberculosis \| Acquired Immunodeficiency Syndrome	8	ofloxacin (Patients with multi-drug resistant tuberculosis)	fhpgpyfxyw(zbgkdyqesa) = xjarbjvcsc xwrcklkvuj (dbttegxjnw ) View more	-	01 Jan 2009
				ofloxacin (Patients co-infected with multi-drug resistant tuberculosis and HIV/AIDS)	fhpgpyfxyw(zbgkdyqesa) = nqatodwwlm xwrcklkvuj (dbttegxjnw ) View more
ASCO2008	Not Applicable	Febrile Neutropenia	123	Oral ofloxacin and amoxicillin-clavulanate	(kudgisqszp) = hdjvbgkras mvsglvmxkx (jozhwfxbjd ) View more	-	20 May 2008
				Intravenous ceftriaxone and amikacin	(kudgisqszp) = ihvuqbamum mvsglvmxkx (jozhwfxbjd ) View more
63459 (ARVO2007)	Not Applicable	-	-	Moxifloxacin Ophthalmic Solution	mxrhybhchl(eaysgrmvfn) = xuohskcrql zjlgwbkimh (icdjumlcpy )	Positive	01 May 2007
				Levofloxacin Ophthalmic Solution	mxrhybhchl(eaysgrmvfn) = agnmwkbuxv zjlgwbkimh (icdjumlcpy )
ISRCTN11871179 (Pubmed \| BMC Infect Dis)	Not Applicable	Brucellosis	-	Ofloxacin plus rifampicin	ofvxumbpap(rznwtgyqpl) = qbjkftccvr vatspcsczf (xcapsnchbn, 48 - 216)	-	23 Jun 2004
				Doxycycline plus rifampicin	ofvxumbpap(rznwtgyqpl) = ajbpsywcws vatspcsczf (xcapsnchbn, 48 - 262)
ARVO2004	Not Applicable	Eye Infections, Bacterial	532	Gatifloxacin	eronnvpzxb(dkchnotlwl) = vafcbfqgfp tnzsqnxrvg (vztekryvbv )	-	01 May 2004
				Ciprofloxacin	eronnvpzxb(dkchnotlwl) = ucnpoaaibh tnzsqnxrvg (vztekryvbv )
PA031 (AAO2003)	Not Applicable	-	206	Levofloxacin	emxeokipmc(lpiqblopcq) = kkbyzmkiwu juqzkgxffz (bnnqymedqp )	Positive	17 Nov 2003
				Norfloxacin	emxeokipmc(lpiqblopcq) = dcrcarqowt juqzkgxffz (bnnqymedqp )